The abnormal metabolism of NAD+ thus leads to multiple diseases, including infection, apoptosis, tumorigenesis, age-associated neurodegeneration disorders, etc. In our research, increasing NAD+ via Olaparib treatment upregulated ENaCα protein expression in NDUFS1 deficient cells and improved alveolar fluid clearance (AFC) in LPS-induced ALI. Here, SCNN1A is linked to infection.